Abstract
Abstract 1378
Poster Board I-400
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is rapidly fatal without specific therapy. In a recently published population-based study we showed large differences in 1- and 5-year relative survival in AML patients in Sweden depending on age at diagnosis and year of diagnosis[1]. Here we use an alternative approach to study patient survival that simultaneously estimates the proportion of patients cured from AML and the survival time of those patients that are not cured. The cure proportion provides a better estimate of long-term survival than 5-year survival and is therefore of direct interest to patients and health care professions.
We conducted a population-based cohort study including 6,439 patients aged 19-79 diagnosed with AML in Sweden 1973 to 2001. Patients are considered statistically cured when, as a group, their mortality returns the level of a comparable general population. We estimated mixture cure fraction models that provide estimates of both the cure proportion and the distribution of survival times of the “uncured”. Age at diagnosis was classified into four categories 19-40, 41-60, 61-70 and 71-80 and year of diagnosis was modeled using restricted cubic splines.
During the first years of the study period the cure fraction was less than 5% for all age groups and the median survival time for “uncured” approximately 0.5 years or less. In 2000 the estimated cure proportion was 68% (95% CI 56%-77%) for the youngest age group, 32% (25-39%) for those aged 41-60, 8.4% (3.1-21%) for those aged 61-70 at diagnosis and 4.3% (2.3-8.1%) for the oldest age group. The estimated median survival times for “uncured” were 0.74 (0.43-1.26), 0.71 (0.53-0.97), 0.69 (0.51-0.95) and 0.37 (0.31-0.44) years respectively (Table 1). The improvement in survival manifested as longer survival among the uncured during the early calendar years but increases in the cure proportion were observed during later years.
There are large differences in the proportion cured between the age groups. In younger patients the cure proportion has increased dramatically, while survival of the “uncured” actually decreased in the last time period. In the older age groups improvement is merely seen within the survival of the “uncured”.
Year . | Age group (years) . | |||
---|---|---|---|---|
19-40 . | 41-60 . | 61-70 . | 71-80 . | |
The cure fraction (%) | ||||
1975 | 4 (2-10) | 3 (2-7) | 6 (3-9) | 3 (2-6) |
1990 | 29 (23-35) | 15 (12-19) | 7 (4-10) | 3 (2-5) |
2000 | 68 (56-77) | 32 (25-39) | 8 (3-21) | 4 (2-8) |
Median survival of “uncured” (years) | ||||
1975 | 0.43 (0.32-0.58) | 0.34 (0.27-0.44) | 0.20 (0.16-0.25) | 0.15 (0.12-0.18) |
1990 | 1.08 (0.90-1.31) | 0.91 (0.78-1.05) | 0.61 (0.52-0.70) | 0.24 (0.21-0.28) |
2000 | 0.74 (0.43-1.26) | 0.71 (0.53-0.97) | 0.69 (0.51-0.95) | 0.37 (0.31-0.44) |
Time at which 90% of the “uncured” are dead (years) | ||||
1975 | 2.75 (2.04-3.78) | 2.42 (1.87-3.12) | 1.24 (0.98-1.58) | 0.86 (0.70-1.05) |
1990 | 3.64 (3.00-4.42) | 4.26 (3.55-5.10) | 3.23 (2.70-3.85) | 1.67 (1.45-1.93) |
2000 | 3.21 (1.80-5.73) | 4.10 (2.77-6.07) | 3.92 (2.42-6.36) | 2.13 (1.72-2.63) |
Year . | Age group (years) . | |||
---|---|---|---|---|
19-40 . | 41-60 . | 61-70 . | 71-80 . | |
The cure fraction (%) | ||||
1975 | 4 (2-10) | 3 (2-7) | 6 (3-9) | 3 (2-6) |
1990 | 29 (23-35) | 15 (12-19) | 7 (4-10) | 3 (2-5) |
2000 | 68 (56-77) | 32 (25-39) | 8 (3-21) | 4 (2-8) |
Median survival of “uncured” (years) | ||||
1975 | 0.43 (0.32-0.58) | 0.34 (0.27-0.44) | 0.20 (0.16-0.25) | 0.15 (0.12-0.18) |
1990 | 1.08 (0.90-1.31) | 0.91 (0.78-1.05) | 0.61 (0.52-0.70) | 0.24 (0.21-0.28) |
2000 | 0.74 (0.43-1.26) | 0.71 (0.53-0.97) | 0.69 (0.51-0.95) | 0.37 (0.31-0.44) |
Time at which 90% of the “uncured” are dead (years) | ||||
1975 | 2.75 (2.04-3.78) | 2.42 (1.87-3.12) | 1.24 (0.98-1.58) | 0.86 (0.70-1.05) |
1990 | 3.64 (3.00-4.42) | 4.26 (3.55-5.10) | 3.23 (2.70-3.85) | 1.67 (1.45-1.93) |
2000 | 3.21 (1.80-5.73) | 4.10 (2.77-6.07) | 3.92 (2.42-6.36) | 2.13 (1.72-2.63) |
[1] Derolf AR, Kristinsson SY, Andersson TM-L, Landgren O, Dickman PW, Björkholm M. Improved patient survival for acute myeloid leukemia: A population-based study of 9,729 patients diagnosed in Sweden 1973-2005. Blood. 2009 Apr 16;113(16):3666-72.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.